Shionogi’s Osphena May Offer Safer Alternative To Estrogen
This article was originally published in The Pink Sheet Daily
Executive Summary
The first oral alternative to vaginal or oral steroidal estrogens for treatment of dyspareunia due to menopause appears to have lower risks of stroke and deep vein thrombosis, according to FDA labeling.
You may also be interested in...
Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal
The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio